Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingfanghuopujiedu mixture
- Development stage
- Unknown
- Lead developer
- Hospital of Chengdu University of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Jingfanghuopujiedu mixture (also known as Xinguan No. 3) is a traditional Chinese medicine (TCM) hospital preparation developed by the Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Provincial Hospital of Traditional Chinese Medicine) for the treatment of COVID-19. It is formulated based on the modification of Jingfang Baidu Powder (荆防败毒散) and Huopu Xiaoling Decoction (藿朴夏苓汤) to target the 'wind-cold with dampness' syndrome (风寒夹湿证) of respiratory infections. During the COVID-19 outbreak in early 2020, it was approved under emergency procedures in Sichuan Province, China, and temporarily covered by medical insurance for use in designated COVID-19 treatment hospitals. Clinical trials, including real-world studies, have evaluated its efficacy and safety in improving clinical symptoms and reducing fever in patients with suspected or confirmed COVID-19.
- Other names
- Jingfang Huopu Jiedu MixtureJingfanghuopujiedu MixtureXin-Guan-3 formulaXin-Guan3 formulaXin-Guan 3 formulaXinguan 3Xinguan3Xinguan-3Xinguan No. 3新冠3号新冠三号荆防藿朴解毒合剂
02
Targets
IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Jingfanghuopujiedu mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jingfanghuopujiedu mixture.